Header Logo

Connection

Stephen Eeden to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Stephen Eeden has written about Prostatic Neoplasms.
Stephen Eeden
Connection Strength
9.609
Prostatic Neoplasms
  1. A Large-Scale Association Study Detects Novel Rare Variants, Risk Genes, Functional Elements, and Polygenic Architecture of Prostate Cancer Susceptibility. Cancer Res. 2021 04 01; 81(7):1695-1703.
    View in: PubMed
    Score: 0.607
  2. Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. Nat Commun. 2019 07 15; 10(1):3107.
    View in: PubMed
    Score: 0.551
  3. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. J Urol. 2021 Apr; 205(4):1047-1054.
    View in: PubMed
    Score: 0.303
  4. Long-term follow-up of a racially and ethnically diverse population of men with localized prostate cancer who did not undergo initial active treatment. Cancer Med. 2020 11; 9(22):8530-8539.
    View in: PubMed
    Score: 0.299
  5. Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. Med Decis Making. 2019 11; 39(8):962-974.
    View in: PubMed
    Score: 0.281
  6. A genome-wide association study of prostate cancer in Latinos. Int J Cancer. 2020 04 01; 146(7):1819-1826.
    View in: PubMed
    Score: 0.275
  7. Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. Transl Behav Med. 2018 03 01; 8(2):156-165.
    View in: PubMed
    Score: 0.251
  8. Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance. BMC Cancer. 2018 01 02; 18(1):2.
    View in: PubMed
    Score: 0.248
  9. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. Eur Urol. 2018 01; 73(1):129-138.
    View in: PubMed
    Score: 0.244
  10. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017 Oct 10; 117(8):1233-1240.
    View in: PubMed
    Score: 0.242
  11. Decision-making processes among men with low-risk prostate cancer: A survey study. Psychooncology. 2018 01; 27(1):325-332.
    View in: PubMed
    Score: 0.240
  12. Physicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer. Urology. 2017 09; 107:86-95.
    View in: PubMed
    Score: 0.236
  13. Physicians' perspectives on the informational needs of low-risk prostate cancer patients. Health Educ Res. 2017 04 01; 32(2):134-152.
    View in: PubMed
    Score: 0.235
  14. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
    View in: PubMed
    Score: 0.231
  15. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clin Proc. 2016 Dec; 91(12):1717-1726.
    View in: PubMed
    Score: 0.228
  16. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health. 2006 Jun 30; 6:172.
    View in: PubMed
    Score: 0.223
  17. Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2016 08; 25(8):1240-50.
    View in: PubMed
    Score: 0.222
  18. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.
    View in: PubMed
    Score: 0.220
  19. Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management. J Urol. 2016 Sep; 196(3):734-40.
    View in: PubMed
    Score: 0.220
  20. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015 Jan; 11(1):e1004930.
    View in: PubMed
    Score: 0.202
  21. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
    View in: PubMed
    Score: 0.201
  22. Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):495-502.
    View in: PubMed
    Score: 0.196
  23. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
    View in: PubMed
    Score: 0.191
  24. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013 Dec; 36(12):3953-60.
    View in: PubMed
    Score: 0.186
  25. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract. 2014 Jul-Aug; 8(4):e374-81.
    View in: PubMed
    Score: 0.183
  26. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology. 2013 Aug; 82(2):327-33.
    View in: PubMed
    Score: 0.182
  27. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. Prostate. 2013 Sep; 73(13):1371-7.
    View in: PubMed
    Score: 0.180
  28. Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer. Urology. 2012 May; 79(5):1034-41.
    View in: PubMed
    Score: 0.167
  29. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75.
    View in: PubMed
    Score: 0.153
  30. Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer. 2012 Jan; 20(1):65-73.
    View in: PubMed
    Score: 0.152
  31. Patient recruitment methods to evaluate treatment decision making for localized prostate cancer. Am J Clin Oncol. 2010 Aug; 33(4):381-6.
    View in: PubMed
    Score: 0.148
  32. Unanticipated and underappreciated outcomes during management of local stage prostate cancer: a prospective survey. J Urol. 2010 Jul; 184(1):120-5.
    View in: PubMed
    Score: 0.146
  33. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One. 2010 Jan 15; 5(1):e8736.
    View in: PubMed
    Score: 0.143
  34. Red wine consumption and risk of prostate cancer: the California men's health study. Int J Cancer. 2010 Jan 01; 126(1):171-9.
    View in: PubMed
    Score: 0.142
  35. Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am J Manag Care. 2009 Nov; 15(11):793-9.
    View in: PubMed
    Score: 0.141
  36. Access to information sources and treatment considerations among men with local stage prostate cancer. Urology. 2009 Sep; 74(3):509-15.
    View in: PubMed
    Score: 0.138
  37. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):628-35.
    View in: PubMed
    Score: 0.125
  38. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
    View in: PubMed
    Score: 0.122
  39. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. J Natl Cancer Inst. 2017 08 01; 109(8).
    View in: PubMed
    Score: 0.120
  40. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. Nat Commun. 2017 01 31; 8:14248.
    View in: PubMed
    Score: 0.116
  41. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015 Jul 21; 314(3):265-77.
    View in: PubMed
    Score: 0.105
  42. A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. Cancer Discov. 2015 Aug; 5(8):878-91.
    View in: PubMed
    Score: 0.104
  43. Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. Prev Med. 2004 Jul; 39(1):27-35.
    View in: PubMed
    Score: 0.097
  44. Initial treatment for prostate carcinoma in relation to comorbidity and symptoms. Cancer. 2002 Dec 01; 95(11):2308-15.
    View in: PubMed
    Score: 0.087
  45. Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. Prostate. 2000 May 01; 43(2):136-43.
    View in: PubMed
    Score: 0.073
  46. Increased risk of high-grade prostate cancer among infertile men. Cancer. 2010 May 01; 116(9):2140-7.
    View in: PubMed
    Score: 0.073
  47. Medical history, body size, and cigarette smoking in relation to fatal prostate cancer. Cancer Causes Control. 2010 Jan; 21(1):117-25.
    View in: PubMed
    Score: 0.070
  48. Digital rectal examination and mortality from prostate cancer. Urology. 1999 Apr; 53(4):863-4.
    View in: PubMed
    Score: 0.068
  49. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998 Sep 15; 83(6):1180-8.
    View in: PubMed
    Score: 0.065
  50. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1998 Jul 01; 90(13):986-90.
    View in: PubMed
    Score: 0.064
  51. Racial differences in treatment of early-stage prostate cancer. Urology. 2008 Jun; 71(6):1172-6.
    View in: PubMed
    Score: 0.062
  52. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study. Epidemiology. 2005 May; 16(3):367-76.
    View in: PubMed
    Score: 0.051

© 2024 Kaiser Permanente